Acceder

Publicaciones - CARDIOLOGIA CLINICA Y EXPERIMENTAL

Cargando...
Esteve-Pastor MA, Núñez-Gil IJ, Marín F. The search for optimal anticoagulation therapy in ACS: The gap between clinical trials and current clinical guidelines. Thromb Haemost. 2015 Nov;114(5):872-4. doi: 10.1160/TH15-06-0512. PubMed PMID: 26271308.
AÑO: 2015; IF: 4.385
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225. PubMed PMID: 26630143.
AÑO: 2015; IF: 59.558
Ruiz-Ortiz M, Bertomeu V, Cequier Á, Marín F, Anguita M. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost. 2015 Oct;114(4):695-701. doi: 10.1160/TH15-02-0169. PubMed PMID: 26054407.
AÑO: 2015; IF: 5.255
Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; ELIXA Investigators.. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015 May;169(5):631-638.e7. doi: 10.1016/j.ahj.2015.02.002. PubMed PMID: 25965710.
AÑO: 2015; IF: 4.332
Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M; RIETE investigators.. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Thromb Res. 2015 Apr;135(4):666-72. doi: 10.1016/j.thromres.2015.02.001. PubMed PMID: 25708926.
AÑO: 2015; IF: 2.32
< AnteriorSiguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII